Thelansis’s "Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Ankylosing Spondylitis is a chronic immune-mediated spondyloarthropathy strongly associated with HLA-B27, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by TNF and IL-17 pathway dysregulation. It presents with insidious inflammatory back pain, morning stiffness improving with activity, and variable peripheral joint, ocular, and cardiac involvement. Diagnosis combines clinical criteria, MRI sacroiliitis, and HLA-B27 testing; ASDAS and BASDAI scores alongside structural progression gauge severity. NSAIDs remain first-line; refractory disease warrants TNF inhibitors, IL-17A/F dual blockade with bimekizumab, or JAK inhibitors including upadacitinib. Regular mobility assessment and cardiovascular screening guide monitoring. Early advanced therapy, physiotherapy, and patient education preserve function and quality of life.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.